[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
The currently approved coxibs celecoxib and etoricoxib, have an equivalent effect in comparison with conventional NSAIDs. This has been established both in comparative studies and by several years of practical application. While celecoxib is approved only for the symptomatic treatment of arthrosis and rheumatoid arthritis, etoricoxib can also be employed in the treatment of acute attacks of gout.
Krüger
K
K
Rheumazentrum München und Praxiszentrum St. Bonifatius. Klaus.Krueger@med.uni-muenchen.de
D000208:Acute Disease; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068579:Celecoxib; D018849:Controlled Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000077613:Etoricoxib; D006073:Gout / Q000188:drug therapy; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy; D010919:Placebos; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D016861:Cyclooxygenase Inhibitors; D010919:Placebos; D011720:Pyrazoles; D011725:Pyridines; D013449:Sulfonamides; D013450:Sulfones; D000068579:Celecoxib; D000077613:Etoricoxib